Last reviewed · How we verify

NCT05307601: IMMUNOVIDIAL

Immune Response Following COVID-19 in Hemodialysis Patients

Completed Last updated 1 April 2022
What this trial tests

trial in Dialysis; Complications in 21 participants. Completed in 30 October 2021.

Timeline
1 September 2020
Primary endpoint
1 September 2021
30 October 2021

Quick facts

Lead sponsorAURA Paris
StatusCompleted
Study typeOBSERVATIONAL
Enrollment21
Start date1 September 2020
Primary completion1 September 2021
Estimated completion30 October 2021
Sites1 location across France

Conditions studied

Sponsor

AURA Paris

Who can join

18 and older, any sex, with Dialysis; Complications or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with chronic kidney disease (CKD), particularly those undergoing hemodialysis (HD), are at high risk of a severe form of COVID-19. This study aims to characterize the inflammatory and antiviral response during SarsCov2 infection in adult

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dialysis; Complications

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05307601.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing